

Florian Lordick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1721071/publications.pdf>

Version: 2024-02-01

118
papers

16,158
citations

76326

40
h-index

32842

100
g-index

126
all docs

126
docs citations

126
times ranked

14580
citing authors

#	ARTICLE	IF	CITATIONS
1	Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. <i>Lancet</i> , The, 2010, 376, 687-697.	13.7	5,899
2	Gastric cancer. <i>Lancet</i> , The, 2020, 396, 635-648.	13.7	2,084
3	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2010, 11, 38-47.	10.7	873
4	PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. <i>Lancet Oncology</i> , The, 2007, 8, 797-805.	10.7	757
5	Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 490-499.	10.7	740
6	Oesophageal cancer. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17048.	30.5	671
7	Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954. <i>Journal of Clinical Oncology</i> , 2010, 28, 5210-5218.	1.6	619
8	Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction. <i>Journal of Clinical Oncology</i> , 2006, 24, 4692-4698.	1.6	458
9	ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). <i>BMC Cancer</i> , 2016, 16, 503.	2.6	234
10	Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma. <i>JAMA Oncology</i> , 2017, 3, 620.	7.1	233
11	TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROC, EORTC and CCTG. <i>Annals of Surgical Oncology</i> , 2017, 24, 2252-2258.	1.5	186
12	Unmet needs and challenges in gastric cancer: The way forward. <i>Cancer Treatment Reviews</i> , 2014, 40, 692-700.	7.7	156
13	TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, Tj ETQq1 1 02784314 rg84 /Over	1.5	186
14	Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 473-487.	27.6	139
15	Clinical impact of tumour biology in the management of gastroesophageal cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 348-360.	27.6	132
16	The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. <i>Cancer</i> , 2006, 106, 2119-2127.	4.1	131
17	A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. <i>Annals of Oncology</i> , 2019, 30, 1487-1495.	1.2	130
18	Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer – Differential treatment strategies for subtypes of early gastroesophageal cancer. <i>European Journal of Cancer</i> , 2012, 48, 2941-2953.	2.8	129

#	ARTICLE	IF	CITATIONS
19	Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: Report of three cases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1295-1298.	0.8	128
20	Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS - a randomised controlled multicentre trial (ISRCTN30964555). <i>BMC Cancer</i> , 2012, 12, 142.	2.6	115
21	Imaging Gastric Cancer with PET and the Radiotracers 18F-FLT and 18F-FDG: A Comparative Analysis. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1945-1950.	5.0	113
22	Optimal chemotherapy for advanced gastric cancer: is there a global consensus?. <i>Gastric Cancer</i> , 2014, 17, 213-225.	5.3	103
23	Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. <i>Modern Pathology</i> , 2009, 22, 1555-1563.	5.5	101
24	Recent advances in multimodal treatment for gastric cancer: a review. <i>Gastric Cancer</i> , 2005, 8, 78-85.	5.3	80
25	Surgical Factors Influence the Outcome After Ivor-Lewis Esophagectomy with Intrathoracic Anastomosis for Adenocarcinoma of the Esophagogastric Junction: A Consecutive Series of 240 Patients at an Experienced Center. <i>Annals of Surgical Oncology</i> , 2009, 16, 1017-1025.	1.5	79
26	Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. <i>Journal of Nuclear Medicine</i> , 2005, 46, 2029-34.	5.0	71
27	Ultrasound screening for internal jugular vein thrombosis aids the detection of central venous catheter-related infections in patients with haemato-oncological diseases: a prospective observational study. <i>British Journal of Haematology</i> , 2003, 120, 1073-1078.	2.5	65
28	ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer. <i>ESMO Open</i> , 2020, 5, e000804.	4.5	61
29	Randomised phase II trial to investigate catumaxomab (anti-EpCAM—anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. <i>British Journal of Cancer</i> , 2018, 119, 296-302.	6.4	60
30	ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer. <i>ESMO Open</i> , 2020, 5, e000826.	4.5	60
31	Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. <i>European Journal of Cancer</i> , 2015, 51, 569-576.	2.8	59
32	Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). <i>BMC Cancer</i> , 2011, 11, 509.	2.6	58
33	ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 179-193.	4.4	57
34	VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or Tj ETQq0 0 0 gBT /Overlock 10 Tf	4.8	56
35	Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Cancer Patients with Peritoneal Metastasis (PM): Results of a Single-Center Experience and Register Study. <i>Journal of Gastric Cancer</i> , 2018, 18, 379.	2.5	54
36	HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 1468-1478.	1.6	54

#	ARTICLE	IF	CITATIONS
37	Organotypic slice cultures of human gastric and esophagogastric junction cancer. <i>Cancer Medicine</i> , 2016, 5, 1444-1453.	2.8	50
38	Multimodal treatment of esophageal cancer. <i>Langenbeck's Archives of Surgery</i> , 2013, 398, 177-187.	1.9	46
39	HER2 testing in gastric cancer: results of a German expert meeting. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 835-841.	2.5	46
40	Efficacy of a brief manualized intervention Managing Cancer and Living Meaningfully (CALM) adapted to German cancer care settings: study protocol for a randomized controlled trial. <i>BMC Cancer</i> , 2015, 15, 592.	2.6	42
41	Symptom Burden and Palliative Care Needs of Patients with Incurable Cancer at Diagnosis and During the Disease Course. <i>Oncologist</i> , 2021, 26, e1058-e1065.	3.7	42
42	Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 135-144.	7.3	39
43	Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. <i>Oncotarget</i> , 2014, 5, 6620-6632.	1.8	35
44	Death-Related Anxiety in Patients With Advanced Cancer: Validation of the German Version of the Death and Dying Distress Scale. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 582-587.	1.2	34
45	Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. <i>Gastric Cancer</i> , 2017, 20, 904-912.	5.3	33
46	Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801). <i>European Journal of Cancer</i> , 2018, 93, 119-126.	2.8	33
47	Targeting the HGF/MET pathway in gastric cancer. <i>Lancet Oncology</i> , The, 2014, 15, 914-916.	10.7	28
48	Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. <i>European Journal of Cancer</i> , 2022, 164, 18-29.	2.8	27
49	How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?. <i>Current Opinion in Oncology</i> , 2011, 23, 396-402.	2.4	26
50	The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. <i>European Journal of Cancer</i> , 2019, 112, 1-8.	2.8	23
51	Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma. <i>Gastric Cancer</i> , 2021, 24, 721-730.	5.3	23
52	Symptoms and Needs of Head and Neck Cancer Patients at Diagnosis of Incurability - Prevalences, Clinical Implications, and Feasibility of a Prospective Longitudinal Multicenter Cohort Study. <i>Oncology Research and Treatment</i> , 2016, 39, 186-191.	1.2	20
53	SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer. <i>Cancers</i> , 2019, 11, 187.	3.7	20
54	Proteomic and metabolic prediction of response to therapy in gastric cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 13648.	3.3	20

#	ARTICLE	IF	CITATIONS
55	Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. <i>ESMO Open</i> , 2020, 5, e001090.	4.5	18
56	Optimizing Neoadjuvant Chemotherapy Through the Use of Early Response Evaluation by Positron Emission Tomography. <i>Recent Results in Cancer Research</i> , 2012, 196, 201-211.	1.8	18
57	Long-term outcomes of trimodality treatment for squamous cell carcinoma of the esophagus with cisplatin and/or 5-FU. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 1133-1140.	2.0	16
58	Insights into next developments in advanced gastric cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 367-375.	2.4	16
59	Management of Metastatic Gastric Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 469-483.	2.2	16
60	Synchronous metastatic gastric cancer-molecular background and clinical implications with special attention to mismatch repair deficiency. <i>European Journal of Surgical Oncology</i> , 2018, 44, 626-631.	1.0	16
61	Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer. <i>European Journal of Cancer</i> , 2020, 124, 67-76.	2.8	16
62	Adjuvant radiotherapy for gastric cancer—end of the road?. <i>Annals of Oncology</i> , 2021, 32, 287-289.	1.2	16
63	Current treatment approach to locally advanced esophageal cancer: is resection mandatory?. <i>Future Oncology</i> , 2006, 2, 717-721.	2.4	15
64	Targeted and immunotherapy in the era of personalised gastric cancer treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2021, 50-51, 101738.	2.4	15
65	Tumor-associated macrophages and individual chemo-susceptibility are influenced by iron chelation in human slice cultures of gastric cancer. <i>Oncotarget</i> , 2019, 10, 4731-4742.	1.8	15
66	Molecular Targets for Gastric Cancer Treatment and Future Perspectives from a Clinical and Translational Point of View. <i>Cancers</i> , 2021, 13, 5216.	3.7	15
67	The evolving role of catumaxomab in gastric cancer. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1407-1415.	3.1	14
68	PAXgene fixation enables comprehensive metabolomic and proteomic analyses of tissue specimens by MALDI MSI. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2018, 1862, 51-60.	2.4	14
69	Gastric cancer adjuvant therapy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 581-591.	2.4	13
70	Social networks for young patients with cancer: the time for system agility. <i>Lancet Oncology</i> , The, 2019, 20, 765.	10.7	11
71	Young patients with cancer and a digital social network: the voice beyond the clinic. <i>ESMO Open</i> , 2020, 5, e000651.	4.5	9
72	Salvage chemotherapy in gastric cancer—more than a straw?. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 312-313.	27.6	8

#	ARTICLE	IF	CITATIONS
73	Over the RAINBOWâ€™ renaissance in antiangiogenesis. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 7-8.	27.6	8
74	Influence of Taxanes on Treatment Sequence in Gastric Cancer. <i>Oncology Research and Treatment</i> , 2020, 43, 42-47.	1.2	8
75	PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma. <i>OncoImmunology</i> , 2021, 10, 1960729.	4.6	8
76	Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers. <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, 187-97.	0.7	7
77	HER2 in gastric cancer: a biomarker with clinical impact, but not without translational challenges. <i>Clinical and Translational Oncology</i> , 2011, 13, 597-598.	2.4	6
78	Chances, risks and limitations of neoadjuvant therapy in surgical oncology. <i>Innovative Surgical Sciences</i> , 2016, 1, 3-11.	0.7	6
79	Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial. <i>British Journal of Cancer</i> , 2018, 119, 170-175.	6.4	6
80	Two steps forward and one step back. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 69-70.	27.6	6
81	Characterization of Total RNA, CD44, FASN, and PTEN mRNAs from Extracellular Vesicles as Biomarkers in Gastric Cancer Patients. <i>Cancers</i> , 2021, 13, 5975.	3.7	6
82	Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (<scp>LICC</scp>, <scp>CELIM</scp>, <scp>FIRE</scp>â€™). <i>International Journal of Cancer</i> , 2022, 150, 1341-1349.	5.1	6
83	Progress and challenges in gastroesophageal cancer. <i>Current Problems in Cancer</i> , 2020, 44, 100590.	2.0	5
84	Anti-angiogenesis: disappointment in localised oesophagogastric cancer. <i>Lancet Oncology</i> , The, 2017, 18, 278-279.	10.7	4
85	Will molecular target agents enable the multidisciplinary treatment in stage IV gastric cancer?. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1835-1845.	1.0	4
86	Changing paradigms in adjuvant treatment of colorectal cancer. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 6-8.	8.1	4
87	Psychosocial aftercare of adolescent and young adult cancer survivors in Germany: Awareness, utilisation, satisfaction and associated factors. <i>Psycho-Oncology</i> , 2021, 30, 1311-1321.	2.3	4
88	Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapiesâ€™ the role of HAS2, SHB and HBEGF. <i>BMC Cancer</i> , 2022, 22, 254.	2.6	4
89	The role of biologics in stomach cancer. <i>Targeted Oncology</i> , 2008, 3, 71-79.	3.6	3
90	Toward a Routine Assessment of Visceral Adipose Tissue Volume from Computed Tomographic Data. <i>Obesity</i> , 2021, 29, 294-301.	3.0	3

#	ARTICLE	IF	CITATIONS
91	SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells. International Journal of Molecular Sciences, 2021, 22, 82.	4.1	3
92	Magenkarzinom: Neue molekulare Konzepte. , 0, , .		3
93	Perioperative and Palliative Chemotherapy for Esophageal Cancer. Visceral Medicine, 2015, 31, 341-346.	1.3	2
94	High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact. European Journal of Cancer, 2019, 116, 107-113.	2.8	2
95	Treatment of oesophageal cancer – Stressing the patient perspective. European Journal of Cancer, 2017, 84, 360-362.	2.8	1
96	Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty. ESMO Open, 2019, 4, e000533.	4.5	1
97	Rectal Cancer with Synchronous Liver Metastases: Leave It All in? When (not) to Resect the Primary?. Recent Results in Cancer Research, 2014, 203, 231-241.	1.8	1
98	Magenkarzinom: Neue molekulare Konzepte. , 0, , .		1
99	Der Patient im Mittelpunkt. Forum, 2016, 31, 89-90.	0.0	0
100	Salvage chemotherapy for advanced gastric cancer: more than a false hope?. The Lancet Gastroenterology and Hepatology, 2017, 2, 240-241.	8.1	0
101	Anti-Angiogenics in Gastroesophageal Cancer. , 2017, , 1-19.		0
102	Oligometastases of Gastrointestinal Cancer Origin. Visceral Medicine, 2017, 33, 76-81.	1.3	0
103	Krebs ist teuer – eine Frage der Perspektive. Forum, 2018, 33, 299-301.	0.0	0
104	More is more? Pushing chemoradiotherapy of oesophageal squamous cell carcinoma forward. European Journal of Cancer, 2018, 97, 25-26.	2.8	0
105	Ein bewegtes 2019. Forum, 2019, 34, 1-1.	0.0	0
106	Leitlinien und Innovation – kein Widerspruch. Forum, 2019, 34, 223-224.	0.0	0
107	Zu viel Recht?. Forum, 2019, 34, 399-399.	0.0	0
108	Zu viel ist nicht gut. Forum, 2019, 34, 305-305.	0.0	0

#	ARTICLE	IF	CITATIONS
109	Zwei Dekaden gegen den Krebs. Forum, 2019, 34, 489-489.	0.0	0
110	Ärberleben mit QualitÄt. Forum, 2020, 35, 355-355.	0.0	0
111	Technik fÄ¼r das Leben. Forum, 2020, 35, 257-257.	0.0	0
112	Reif fÄ¼r die Insel. Forum, 2020, 35, 433-433.	0.0	0
113	Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2020, 20, 305-324.	2.4	0
114	Die digitale Revolution erreicht die Onkologie. Forum, 2020, 35, 81-81.	0.0	0
115	Äsophaguskarzinom beim alten und geriatrischen Patienten. , 2017, , 1-12.		0
116	Äsophaguskarzinom beim alten und geriatrischen Patienten. , 2018, , 313-324.		0
117	Anti-angiogenics in Gastroesophageal Cancer. , 2019, , 395-414.		0
118	Targeting HER2 for localised oesophageal cancer. Lancet Oncology, The, 2022, 23, 188-190.	10.7	0